Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Lineage Cell Therapeutics (LCTX) has announced the opening of a new R&D facility in Carlsbad, California, along with the expansion of its GMP manufacturing facility in Jerusalem, Israel. These developments aim to enhance R&D capabilities and support current and future allogeneic cell transplant programs. CEO Brian M. Culley emphasized the importance of this expansion in reducing vendor reliance and cutting costs. The investments will help centralize operations while positioning Lineage for future growth. Lineage's clinical programs include therapies for geographic atrophy and acute spinal cord injuries.

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) announced that CEO Brian M. Culley will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference. This fireside chat, hosted by Joseph Pantginis, Ph.D., will be available on demand starting August 17, 2022, at 7 AM ET. Investors can register for the on-demand replay through Lineage's website. The company specializes in developing allogeneic cell therapies targeting significant medical needs.

Lineage Cell Therapeutics reported Q2 2022 financial results, with revenue of approximately $4.6 million, up from $0.5 million in Q2 2021, due to licensing fees from Roche. Despite increased R&D and G&A expenses totaling $8.6 million, the loss from operations decreased to $4.2 million from $7.1 million year-over-year. The cash position stood at $72 million, sufficient to fund operations through Q2 2024. Key developments included advancements in RG6501 (OpRegen) and ongoing regulatory preparations for OPC1 and VAC2. A conference call will provide further business updates.

Lineage Cell Therapeutics (LCTX) announced it will report its Q2 2022 financial results on August 11, 2022, after market close. A conference call will follow at 4:30 p.m. ET. Participants can access the call by dialing (800) 715-9871 in the U.S. and (646) 307-1952 internationally. Lineage specializes in developing allogeneic cell therapies for unmet medical needs, with its pipeline including five candidates targeting conditions like age-related macular degeneration and acute spinal cord injuries.

Lineage Cell Therapeutics has expanded its collaboration with Advanced BioMatrix to include clinical-grade HyStem technology supply for cell therapies. The amended agreement increases milestone payments and royalties for Lineage, enhancing potential revenue streams. CEO Brian M. Culley emphasized a focus on business development and monetizing their technology platform. HyStem, a patented hydrogel, supports various cell types and is crucial for cell functionality. With clinical programs targeting significant market opportunities, this partnership positions Lineage for improved cash flow and supports its development pipeline.

Lineage Cell Therapeutics (LCTX) reported strong financial results for Q1 2022, with revenues increasing to $5.2 million from $0.4 million YoY, attributable to a $50 million licensing payment from Roche. Operating expenses rose to $11.5 million, driven by a $3.5 million one-time expense related to litigation. The company completed patient enrollment for the VAC2 Phase 1 study and showcased promising clinical results for OpRegen in addressing geographic atrophy from AMD. As of March 31, 2022, cash reserves stood at $78.1 million, supporting ongoing clinical and regulatory efforts.

Lineage Cell Therapeutics (LCTX) will report its Q1 2022 financial and operational results on May 12, 2022, post-market closure. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and provide a business update. The call can be accessed via a designated phone line, and a live webcast will be available on their investor website, with replays offered for 30 days. Lineage specializes in developing allogeneic cell therapies, focusing on addressing significant medical needs through innovative cell-based interventions.

Lineage Cell Therapeutics (LCTX) presented data from its Phase 1/2a study of OpRegen, a cell therapy for geographic atrophy (GA) due to age-related macular degeneration (AMD), at the 2022 ARVO Annual Meeting. The 12-month primary endpoint data indicate OpRegen is well-tolerated, showing an acceptable safety profile. Preliminary improvements in visual function were noted in Cohort 4 patients with GA, with an average 7.6 letter gain in visual acuity. These findings support further development of OpRegen as a potential treatment for GA, previously thought to have no effective interventions.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a fireside chat with CEO Brian M. Culley scheduled for April 27, 2022, at 3:30 PM EST. The event will be hosted by Mayank Mamtani, Senior Analyst at B. Riley Securities, focusing on two new cell therapy programs stemming from the collaboration with Roche and Genentech for the RG6501 (OpRegen®) program.

Lineage specializes in developing allogeneic cell therapies, targeting unmet medical needs in significant markets.